Literature DB >> 25227961

Long-term mortality from cardiac causes after adjuvant hypofractionated vs. conventional radiotherapy for localized left-sided breast cancer.

Elisa K Chan1, Ryan Woods2, Sean Virani3, Caroline Speers4, Elaine S Wai5, Alan Nichol6, Mary L McBride2, Scott Tyldesley7.   

Abstract

BACKGROUND AND
PURPOSE: Ongoing concern remains regarding cardiac injury with hypofractionated whole breast/chest-wall radiotherapy (HF-WBI) compared to conventional radiotherapy (CF-WBI) in left-sided breast cancer patients. The purpose was to determine if cardiac mortality increases with HF-WBI relative to CF-WBI.
MATERIALS AND METHODS: Between 1990 and 1998, 5334 women with early-stage breast cancer received post-operative radiotherapy to the breast/chest wall alone. A population-based database recorded baseline patient, tumor and treatment factors. Baseline cardiovascular risk factors were identified from hospital administrative records. A propensity-score model balanced risk factors between radiotherapy groups. Cause of death was coded as breast cancer, cardiac or other cause. Cumulative mortality from each cause after radiotherapy was estimated using a competing risk approach.
RESULTS: For left-sided cases, median follow-up was 14.2 years. 485 women received CF-WBI, 2221 women received HF-WBI. There was no difference in 15-year mortality from cardiac causes: 4.8% with HF-WBI and 4.2% with CF-WBI (p=0.74), even after propensity-score adjustment (p=0.45). There was no difference in breast cancer mortality or other cause mortality. For right-sided cases, there was no difference in mortality for the three causes of death.
CONCLUSIONS: At 15-years follow-up, cardiac mortality is not statistically different among left-sided breast cancer patients treated with HF-WBI or CF-WBI.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cardiac mortality; Hypofractionation

Mesh:

Year:  2014        PMID: 25227961     DOI: 10.1016/j.radonc.2014.08.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  A Study on Dosimetric Outcomes and Acute Toxicity of Post Mastectomy Adjuvant Hypofractionated Radiotherapy for Breast Cancer.

Authors:  Shivaprasad Deshmukh; Krishna Sharan; Donald Jerard Fernandes; Vidyasagar Mamidipudi Srinivasa; Prahlad Hiremagalur Yathiraj; Anshul Singh; Anusha Reddy
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 2.  Emerging Role of Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Modern Radiotherapy of Breast Cancer.

Authors:  Mirko Nitsche; Juergen Dunst; Ulrich M Carl; Robert M Hermann
Journal:  Breast Care (Basel)       Date:  2015-07-10       Impact factor: 2.860

3.  The long-term outcome of adjuvant hypofractionated radiotherapy and conventional fractionated radiotherapy after breast-conserving surgery for early breast cancer: a prospective analysis of 107 cases.

Authors:  Shuhong Zhao; Yi Liu; Fengxian Huang; Xin Chen; Ximing Cao; Jiao Yu
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

4.  Radiation dose to the left anterior descending coronary artery during interstitial pulsed-dose-rate brachytherapy used as a boost in breast cancer patients undergoing organ-sparing treatment.

Authors:  Marcin Sinacki; Krystyna Serkies; Rafał Dziadziuszko; Magdalena Narkowicz; Joanna Kamińska; Joanna Lipniewicz
Journal:  J Contemp Brachytherapy       Date:  2017-02-15

5.  Comparison of Treatment Outcome between Hypofractionated Radiotherapy and Conventional Radiotherapy in Postmastectomy Breast Cancer.

Authors:  Chokaew Tovanabutra; Kanyarat Katanyoo; Pichet Uber; Kittisak Chomprasert; Sitthi Sukauichai
Journal:  Asian Pac J Cancer Prev       Date:  2020-01-01

6.  Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications.

Authors:  Vikneswary Batumalai; Geoff P Delaney; Joseph Descallar; Gabriel Gabriel; Karen Wong; Jesmin Shafiq; Michael Barton
Journal:  Radiother Oncol       Date:  2020-07-25       Impact factor: 6.280

7.  Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: Cohort study of 2 million women from 57 cancer registries in 22 countries.

Authors:  Katherine E Henson; Paul McGale; Sarah C Darby; Max Parkin; Yaochen Wang; Carolyn W Taylor
Journal:  Int J Cancer       Date:  2020-03-04       Impact factor: 7.396

8.  A radiobiological comparison of hypo-fractionation versus conventional fractionation for breast cancer 3D-conformal radiation therapy.

Authors:  Arezoo Kazemzadeh; Iraj Abedi; Alireza Amouheidari; Atefeh Shirvany
Journal:  Rep Pract Oncol Radiother       Date:  2021-02-25

Review 9.  Hypofractionated whole breast radiotherapy: current perspectives.

Authors:  Theodora A Koulis; Tien Phan; Ivo A Olivotto
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-10-27

10.  Practical consensus recommendations regarding role of postmastectomy radiation therapy.

Authors:  D Singh; G Saini; R Koul; V Gupta; D Abrol; S De; P Kulshrestha; S N Hukku; S J Lakshmi; Purvish M Parikh; S Aggarwal
Journal:  South Asian J Cancer       Date:  2018 Apr-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.